Third retinal indication for Eylea 8mg approved in Europe

19 January 2026

The European Commission has granted marketing authorization for Eylea 8mg (aflibercept 8mg, 114.3mg/ml solution for injection) for visual impairment due to macular edema following retinal vein occlusion (RVO) including branch, central and hemiretinal vein occlusion.

RVO is the third indication for Eylea 8mg, a product being jointly developed by Germany’s Bayer (BAYN: DE) and US biotech major Regeneron (Nasdaq: REGN).

Expands the range of retinal indications for Eylea 8mg

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK